Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATYR

Atyr Pharma Inc

May 29 • 04:00PM ET

0.5425

+0.0551 11.30 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: ANIX LONA NRXS COYA CYPH INO KALA CGTX KLRS NRXP

| Held by: VTI IWM VXF VTWO IWO IWC ITOT VTWG RSSL IWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.73	Insider Own	2.48%	Shs Outstand	98.05M	Perf Week	2.65%
Market Cap	53.19M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	4.00%	Shs Float	95.62M	Perf Month	-29.08%
Enterprise Value	-1.81M	PEG	-	EPS next Q	-0.12	Inst Own	57.36%	Short Float	22.37%	Perf Quarter	-43.48%
Income	-70.03M	P/S	279.95	EPS this Y	28.47%	Inst Trans	2.47%	Short Ratio	10.35	Perf Half Y	-29.31%
Sales	0.19M	P/B	0.92	EPS next Y	-7.96%	ROA	-79.17%	Short Interest	21.39M	Perf YTD	-30.72%
Book/sh	0.59	P/C	0.80	EPS next 5Y	11.51%	ROE	-105.32%	52W High	7.29 -92.56%	Perf Year	-87.25%
Cash/sh	0.68	P/FCF	-	EPS past 3/5Y	20.65% 14.76%	ROIC	-102.76%	52W Low	0.40 37.34%	Perf 3Y	-76.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-73.65% -55.14%	Gross Margin	-723.16%	Volatility	7.36% 14.83%	Perf 5Y	-88.05%
Dividend TTM	-	EV/Sales	-9.53	EPS Y/Y TTM	8.93%	Oper. Margin	-38573.68%	ATR (14)	0.08	Perf 10Y	-98.80%
Dividend Ex-Date	-	Quick Ratio	5.78	Sales Y/Y TTM	-19.15%	Profit Margin	-36857.37%	RSI (14)	42.64	Recom	2.11
Dividend Gr. 3/5Y	- -	Current Ratio	5.78	EPS Q/Q	35.99%	SMA20	-15.96%	Beta	0.54	Target Price	2.86
Payout	-	Debt/Eq	0.20	Sales Q/Q	-	SMA50	-26.99%	Rel Volume	2.61	Prev Close	0.49
Employees	58	LT Debt/Eq	0.18	Earnings	May 15 BMO	SMA200	-58.47%	Avg Volume	2.07M	Price	0.54
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.98% -	Trades		Volume	5,392,012	Change	11.30%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$1.50
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$1
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform	$1
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-18-25	Initiated	Leerink Partners	Outperform	$16
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight	$17
Sep-05-24	Initiated	Jefferies	Buy	$9
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral

Show Previous Ratings

May-15-26 08:06AM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press) -9.98%
08:00AM	aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update (GlobeNewswire)
May-13-26 04:01PM	aTyr Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) -25.33% +41.42%
May-11-26 04:01PM	aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting (GlobeNewswire) -44.20%
Mar-05-26 04:10PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance) -6.45% -8.68%
04:01PM	Loading…
04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update (GlobeNewswire)
Feb-20-26 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-26 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-03-26 08:00AM	aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis (GlobeNewswire)
Nov-25-25 04:08PM	aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman (PR Newswire)
Nov-20-25 01:27PM	aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman (Newsfile)
Nov-18-25 02:03PM	ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman (PR Newswire)
Nov-11-25 09:23AM	aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman (PR Newswire)
Nov-10-25 08:00AM	aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 04:48PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.35% +6.05%
04:01PM	Loading…
04:01PM	aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update (GlobeNewswire)
08:35AM	Investors in aTyr Pharma, Inc. (ATYR): Protect Your Rights - Contact Levi & Korsinsky Before December 8, 2025 (Newsfile)
Oct-23-25 01:11PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (Newsfile)
Oct-21-25 09:00AM	Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR (PR Newswire)
Oct-15-25 02:05PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (Business Wire)
Oct-14-25 08:20AM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (PR Newswire) +7.68%
Oct-10-25 07:06PM	aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATYR (Business Wire) +11.23% -8.89%
Oct-09-25 10:18PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (PR Newswire)
Sep-30-25 05:30AM	aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 (GlobeNewswire) -9.28%
Sep-23-25 09:22AM	aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman (PR Newswire) -5.70%
Sep-17-25 09:03AM	aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman (PR Newswire) -5.09%
Sep-16-25 07:20AM	aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail (Clinical Trials Arena) +6.40%
Sep-15-25 08:11AM	ATyr shares plunge on trial miss in inflammatory lung disease (BioPharma Dive) -83.17%
07:30AM	aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire)
Sep-11-25 10:15AM	1 Small-Cap Biotech Stock Poised for a Breakout (Motley Fool)
03:31AM	Loading…
03:31AM	Lead Therapy Trial Fuels aTyr Pharma's (ATYR) Promising Upside, Leerink Stays Bullish (Insider Monkey)
Sep-08-25 12:30AM	Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results (Insider Monkey)
Sep-05-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.02%
Aug-20-25 12:22AM	ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations (Insider Monkey) +5.58%
Aug-07-25 04:41PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update (GlobeNewswire)
Jul-31-25 10:40AM	Martin Shkreli Is Shorting This Strong Buy Penny Stock. How Should You Play Shares Here? (Barchart)
Jul-22-25 08:00AM	aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire) -8.23%
Jun-26-25 08:00AM	aTyr Pharma to be Added to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-04-25 08:00AM	aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
May-21-25 11:21AM	aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential (Insider Monkey) +7.45%
May-20-25 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-19-25 08:00AM	aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +5.20%
May-16-25 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.00%
May-14-25 08:00AM	aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis (GlobeNewswire) -8.46%
May-09-25 08:32AM	Is aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 04:01PM	aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update (GlobeNewswire) +5.70%
Apr-29-25 08:00AM	aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire) -5.74%
Mar-27-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:27PM	Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-26-25 08:00AM	aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise (GlobeNewswire) -7.16%
Mar-19-25 09:40AM	Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-25 03:11AM	aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Mar-13-25 04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update (GlobeNewswire) +12.39%
Mar-12-25 04:00PM	aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine (GlobeNewswire) +15.64%
Mar-06-25 04:02PM	aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +10.39%
Mar-04-25 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results (GlobeNewswire) -8.18%
Feb-24-25 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -11.34%
Jan-29-25 08:00AM	aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Dec-17-24 08:00AM	aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 04:00PM	aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors (GlobeNewswire)
Dec-10-24 08:00AM	aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) -6.80%
Dec-09-24 08:00AM	aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis (GlobeNewswire) +5.06%
Nov-15-24 08:00AM	aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis (GlobeNewswire) -8.93%
Nov-07-24 04:01PM	aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Oct-31-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-14-24 08:00AM	aTyr Pharma to Present at the LD Micro Main Event XVII in October (Newsfile)
Oct-08-24 08:00AM	aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting (GlobeNewswire)
Oct-02-24 08:00AM	aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal (GlobeNewswire)
Aug-21-24 08:00AM	aTyr Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-24 04:00PM	aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update (GlobeNewswire) +6.32%
Aug-06-24 08:00AM	aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations (GlobeNewswire)
Jul-30-24 08:00AM	aTyr Pharma Announces Research Study with Stanford Medicine (GlobeNewswire) -6.60%
Jul-22-24 08:00AM	aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) +13.41%
Jun-18-24 09:40AM	Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year? (Zacks) -6.78%
Jun-10-24 10:52AM	ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023 (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
Jun-03-24 08:00AM	aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from LIFE to ATYR (GlobeNewswire) +6.94%
May-24-24 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 07:00AM	aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference (GlobeNewswire) +5.22%
May-14-24 08:00AM	aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +7.06%
May-06-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-24 09:58PM	LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:15PM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Apr-01-24 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire)
Mar-26-24 02:19PM	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-15-24 01:33PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript (Insider Monkey) +22.84%
11:30AM	Q4 2023 aTyr Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
11:01AM	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress (GuruFocus.com)
Mar-14-24 08:56PM	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:16PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results (GlobeNewswire) -5.00%
Feb-21-24 08:00AM	aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants (GlobeNewswire)
Jan-29-24 08:00AM	aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity (GlobeNewswire)
Jan-18-24 08:00AM	aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor (GlobeNewswire)
Nov-13-23 08:00AM	aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 (GlobeNewswire)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

M.S.Dr. Sanjay S. Shukla M.D.

Chief Financial OfficerMs. Jill M. Broadfoot CPA

General Counsel & Corporate SecretaryMs. Nancy E. Denyes Krueger J.D.

Director of Investor Relations & Corporate CommunicationsMs. Ashlee Dunston

Vice President of Corporate DevelopmentMr. Peter Villiger

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHIMMEL PAUL	Director	May 27 '26	Buy	0.50	100,000	49,630	779,143	May 28 04:12 PM
Shukla Sanjay	President and CEO	Feb 04 '26	Sale	0.98	3,745	3,655	153,553	Feb 04 07:17 PM
Broadfoot Jill Marie	Chief Financial Officer	Feb 04 '26	Sale	0.98	1,558	1,521	37,296	Feb 04 07:15 PM
DENYES NANCY	General Counsel	Feb 04 '26	Sale	0.98	1,118	1,091	33,124	Feb 04 07:12 PM
SCHIMMEL PAUL	Director	Oct 08 '25	Buy	0.90	682,001	612,437	1,095,024	Oct 09 06:30 PM
SCHIMMEL PAUL	Director	Oct 09 '25	Buy	0.94	317,999	299,364	1,413,023	Oct 09 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATYR

Atyr Pharma Inc

Upgrade your Finviz experience